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35-kDa isoform and its association with poor prognosis in cancers. Here, by employing a novel
monoclonal antibody, the authors found that the 24-kDa LAPTM4B isoform predominated in most, both
healthy and malignant, human cells and tissues studied. LAPTM4B-24 lacks the extreme N-terminus and,
contrary to LAPTM4B-35, failed to promote cell migration. The endogenous LAPTM4B-24 protein was
subject to rapid turnover with a t1/2 of approximately 1 hour. The protein was degraded by both
lysosomal and proteasomal pathways, and its levels were increased by the availability of nutrients and
lysosomal ceramide. These findings underscore the pathophysiological relevance of the LAPTM4B-24
isoform and identify it as a dynamically regulated effector in lysosomal nutrient signaling.
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Disclosures: None declared.The late endosomal/lysosomal protein LAPTM4B was
originally identified from a transcript up-regulated in hepa-
tocellular carcinoma,1 and its expression has been correlated
with poor prognosis in several cancers.2,3 The LAPTM4B
mRNA contains alternative start codons and may be trans-
lated into either a 35-kDa protein (LAPTM4B-35) or a
24-kDa isoform (LAPTM4B-24) lacking amino acids 1 to
91.1 The LAPTM4B-35especific N-terminus has been
reported to contain two functional amino acid motifs, an
SH3-domain binding motif (amino acids 12 to 15) inter-
acting with the p85a subunit of phosphatidylinositol 3-ki-
nase (PI3K) to promote efflux of chemotherapeutic drugs,4
and an arginine-rich polybasic stretch (amino acids 52 to
67) interacting with phosphoinositides to regulate auto-
phagy.5 Both LAPTM4B isoforms have in common the
following motifs: a conserved sphingolipid interaction motif
in the third transmembrane span (amino acids 208 to 216)
important for mammalian target of rapamycin complex 1
(mTORC1) signaling,6 C-terminal lysosomal targeting sig-
nals,1,7 and PY motifs (amino acids 295 to 298, 311 to 314)
required for binding the ubiquitin ligase Nedd4.7stigative Pathology. Published by Elsevier Inc
Y-NC-ND license (http://creativecommons.orgLAPTM4B-35 represents the longest open reading frame
(ORF) of the LAPTM4B transcript, and is commonly
considered to be the major isoform.8 Consequently, most
investigations have focused on LAPTM4B-35, whereas less
is known about LAPTM4B-24. Studies of LAPTM4B have
been hampered by a lack of tools to reliably detect the
endogenous protein, and mechanistic studies have therefore
mainly been conducted in overexpression systems. In cases
where commercially available antibodies have been used to
detect LAPTM4B, proper validation of the detected isoforms
has been lacking. Here, the authors validated a monoclonal
LAPTM4B antibody and investigated the expression of
LAPTM4B isoforms in a range of cell lines, and in healthy
and diseased human tissues. The antibody also enabled the
authors to study, for the first time, how the endogenous.
/licenses/by-nc-nd/4.0).
Expression and Regulation of LAPTM4B-24LAPTM4B protein levels are regulated. Further studies were
performed comparing the functional differences between the
two protein isoforms. It was found that LAPTM4B-24 and
-35 expression induce different cellular phenotypes, and that
LAPTM4B-24 is the dominant isoform in both healthy and
diseased tissues and cells.
Materials and Methods
Cell Culture
The cancer cell lines were from ATCC (Manassas, VA), and
healthy fibroblasts were from Coriell Institute (Camden, NJ).
All cells were grown at þ37C and with 5% CO2; the full
culture conditions are listed in Supplemental Table S1. For
mTORC1 activity experiments, cells were starved for 1 hour
with Earle’s Balanced Salt Solution (EBSS) and subsequently
refed with stimulation medium (EBSS/complete medium; 1:1)
for the indicated time points. To assess the effect of glucose on
LAPTM4B expression, cells were starved for 2 hours or
6 hours in Dulbecco’s Modified Eagle Medium containing no
glucose (Gibco, Waltham, MA; catalog number 11966025).
Reagents, Antibodies, siRNAs, and Quantitative PCR
C6-ceramide (Enzo Clinical Labs, Farmingdale, NY; catalog
number BML-SL110-0005); C6-sphingomyelin (Larodan,
Solna, Sweden; catalog number 56-1083-4); oleic acid (Sigma-
Aldrich, St. Louis, MO; catalog number O-1383); fatty acid-
free bovine serum albumin (Sigma-Aldrich; catalog number
A3803); oleic acid in complex with fatty acid-free bovine
serum albumin (BSA) in 8:1molar ratio prepared in serum-free
Dulbecco’s Modified Eagle Medium for oleic acid loading
cells. Cholesterol (Sigma-Aldrich; catalog number C8669);
methyl beta cyclodextrin (Sigma-Aldrich; catalog number
C4555); cholesterol in complex with methyl beta cyclodextrin
was prepared in ddH2O and subjected to sonication, and then
used for cholesterol loading cells. The following reagents were
also used: cycloheximide (Sigma-Aldrich; catalog number
C-7698); bafilomycin-A1 (AppliChem, Darmstadt, Germany;
catalog number 88899-55-2); MG-132 (Calbiochem, San
Diego, CA; catalog number 474790); dextran TMR (tetrame-
thylrhodamine) (Thermo Fisher Scientific, Waltham, MA;
catalog number D1818). The following antibodies were used:
mouse monoclonal anti-LAPTM4B antibody (Atlas Anti-
bodies, Bromma, Sweden; catalog number AMAb91356);
mouse monoclonal anti-Flag (M2) antibody (Sigma-Aldrich;
catalog number F1804); phospho-p70 S6 Kinase (Thr389)
antibody (Cell Signaling Technology, Danvers, MA; catalog
number 9205); S6 kinase antibody (SantaCruzBiotechnology,
Dallas, TX; catalog number sc-8418); phospho-4E-BP1
(Thr37/46) antibody (Cell Signaling Technology; catalog
number 2855); 4E-BP1 antibody (Cell Signaling Technology;
catalog number 9452); phospho-ULK1 (Ser 757) antibody
(Cell Signaling Technology; catalog number 6888); ULK1
antibody (Cell Signaling Technology; catalog number 8054);The American Journal of Pathology - ajp.amjpathol.orgphospho-AKT (Ser 473) antibody (Cell Signaling Technol-
ogy; catalog number 4060); pan-AKT (C67E7) antibody (Cell
Signaling Technology; catalog number 4691); goat anti-mouse
IgG (Hþ L)-HRP conjugate (Bio-Rad Laboratories, Hercules,
CA; catalog number 1706516); goat anti-mouse IgG (H þ L)
Cross-Adsorbed Secondary Antibody, Alexa Fluor 488
(Thermo Fisher Scientific; catalog number A-11001). The pre-
designed Silencer Select LAPTM4B siRNA (50-GGAUCA-
GUAUAACUUUUCATT-30), SMPD1 siRNA (50-UCACAG
CACUUGUGAGGATT-30), GBA siRNA (50-GGAAUCG-
GAUAUAACAUCATT-30), and Ctrl siRNA were from
Ambion (Waltham, MA). All siRNAs were used at a final
concentration of 10 nmol/L, and cells were transfected 2 to
3 days by HiPerFect transfection reagent (Qiagen, Hilden,
Germany; catalog number 301705).
Quantitative PCR and primers for detecting LAPTM4B
and GAPDH were reported previously.9
Generation of Knockout Cells and Stable Cell Lines
LAPTM4B knockout (KO) A431 and ASAH1 KO A431
were generated by CRISPR/Cas9-mediated genome engi-
neering as described previously.6,9 Briefly, coding
sequences in exon 3 of LAPTM4B (Gene ID: 55,353) and
exon 1 of ASAH1 (Gene ID: 427) were selected and
analyzed for the design of Cas9 nickase targets (CRISPR,
http://crispr.mit.edu, last accessed June 12, 2015). sgRNA
(single guide RNA) guides were synthesized and
subcloned into the sgRNA expression vector using BbsI
sites. Cells were cotransfected with Cas9 nickase and
sgRNA expressing plasmids using Lipofectamine LTX
with PLUS reagent (Invitrogen, Carlsbad, CA; catalog
number 15338100). The cells were under puromycin
(1 mg/mL) selection for 48 hours post-transfection, and
cultured without puromycin for another 4 days. Subse-
quently, single clones were isolated and verified by Sanger
sequencing and Western blotting. For generating cell lines
with missense mutations at LAPTM4B-35 and LAPTM4B-
24 start codon, CRISPR/Cas9 and homology-directed repair
methods were used as described previously.10 For gener-
ating stable LAPTM4B isoformeexpressing cell lines, cells
were transfected with pEFIRES-p containing LAPTM4B-
35-3xFlag, LAPTM4B-24-3xFlag, using Lipofectamine
LTX with PLUS reagent. Cells were grown in culture me-
dium containing 1 mg/mL puromycin until a resistant cell
pool was formed. mCherry-tagged LAPTM4B-35 was
transfected in LAPTM4B-24-3xFlag stable cells to generate
the double-tagged stable cell line.
Western Blotting
Cells were washed with phosphate-buffered saline (PBS),
scraped in NP-40 lysis buffer (1%NP-40, 50 mmol/L HEPES,
250 mmol/L NaCl, 5 mmol/L EDTA, proteinase inhibitor
cocktail, pH 7.4), incubated on ice for 10 minutes, and cleared
by centrifugation at 12,000  g for 10 minutes at 4C. For2019
Zhou et aldetecting protein phosphorylation, cells were washed with
PBS, scraped in SDS boiling buffer (2.5% SDS, 250 mmol/L
Tris/HCl pH 6.8, including 50 mmol/L NaF, 10 mmol/L
b-glycerophosphate, 0.5 mmol/L DTT, 0.5 mmol/L PMSF),
and lysates were boiled at 98C for 10 minutes, and cleared by
centrifugation at 12,000  g for 10 minutes at 4C. Equal
amounts of proteins were resolved on 12%Mini-Protean TGX
Stain-Free gels (Bio-Rad Laboratories; catalog number
161-0185) and transferred onto LF-PVDF (Bio-Rad Labora-
tories; catalog number 170-4274). Membranes were blocked
with 5% milk or 3% BSA in TBS containing 0.1% Tween-20
for 1 hour at room temperature and subsequently probed with
primary antibodies (anti-LAPTM4B, 1:1000; anti-Flag M2,
1:1000 to 1:2000; antiephospho-p70 S6K, 1:1000 to 1:2000;
anti-S6K, 1:1000; antiephospho-4EBP, 1:1000 to 1:2000;
anti-4EBP, 1:1000; antiephospho-ULK1, 1:1000; anti-
ULK1, 1:1000; antiephospho-AKT, 1:1000; anti-AKT,
1:1000) at 4C overnight. After washing with TBS contain-
ing 0.1% Tween-20, membranes were incubated with sec-
ondary antibodies for 45 minutes at room temperature.
Membranes were washed, incubated with ECL Clarity (Bio-
RadLaboratories; catalog number 170-5060), and imagedwith
a ChemiDoc MP Imaging System (Bio-Rad Laboratories;
catalog number 17001402). Band intensities were analyzed
using Image Lab software version 6.0 (Bio-Rad Laboratories),
and were normalized to total protein content quantified with
Stain-Free technology (Bio-Rad Laboratories). The total pro-
tein in each lane served as loading control.Surface Biotinylation
The cell surface biotinylation assay was modified from a
previously published protocol.11 Briefly, cells on 60-mm
plates were rinsed twice with ice-cold PBS containing
0.02 mmol/L CaCl2 and 0.15 mmol/L MgCl2. Cell surface
proteins were biotinylated for 20 minutes with 0.5 mg/mL
biotin (Sulfo-NHS-LC-Biotin; Thermo Fisher Scientific;
catalog number 21335) diluted in PBS. Unbound biotin was
quenched with PBS containing 0.1 mol/L glycine and 0.3%
BSA. The cells were washed with PBS and suspended in
500 mL of lysis buffer (0.2% SDS, 2% NP-40 in PBS,
supplemented with protease inhibitor cocktail; Sigma-
Aldrich; catalog number P8340). After a 10-minute incu-
bation at 4C, lysates were collected and cleared by
centrifugation, and an aliquot (30 mL) was taken for
immunoblotting with the anti-Flag antibody to analyze
protein amount before pulldown. Biotinylated proteins from
the rest of the lysate were captured with 20 mL of strepta-
vidin agarose beads (Sigma-Aldrich; catalog number S1638)
on a rotating mixer (20 rpm) overnight at 4C. Post-
pulldown supernatant was collected to assess the amount
of non-plasma membraneeassociated protein. The beads
were washed, and biotinylated proteins were eluted ac-
cording to the manufacturer’s instructions; the proteins were
analyzed by Western blotting as described above.2020Immunofluorescence Staining and Confocal Microscopy
Immunofluorescence staining was performed as described
previously.6 Briefly, cells were fixed in 4% para-
formaldehyde in PBS for 20 minutes at room temperature
and then quenched with 50 mmol/L NH4Cl for 10 minutes.
Cells were washed with PBS and permeabilized with 0.1%
Triton X-100 in PBS for 10 minutes, blocked in 10% FBS in
PBS for 30 minutes, and then incubated with anti-Flag
M2 (Sigma-Aldrich; catalog number F1804, 1:400) or
anti-LAPTM4B (Atlas Antibodies; catalog number
AMAb91356, 1:200) for 45 minutes at 37C. Cells were
washed in PBS and incubated with secondary antibodies for
45 minutes at 37C. Coverslips were washed in PBS, rinsed
in MQ-H2O (Merck Millipore, Burlington, MA), and
mounted on microscope slides using Mowiol/DABCO
(Calbiochem, San Diego, CA; catalog number 475904/
Sigma-Aldrich; catalog number D-2522). For visualizing
endosomes, cells was treated with 50 mg/mL dextran TMR
(Thermo Fisher Scientific; catalog number D1818) for 2
hours. Images were captured with a Leica TCS SP8 X
confocal microscope (Leica Microsystems, Wetzlar, Ger-
many) and analyzed using ImageJ software version 1.50b
(NIH, Bethesda, MD; http://imagej.nih.gov/ij).
Cell Migration Assay
Cell migration was measured by using xCELLigene.12 Briefly,
the CIM-Plate 16 (ACEA, San Diego, CA; catalog number
5665817001) was equilibrated at 37C for 1 hour with serum-
free medium in the top chamber and complete medium with
10% FBS in the lower chamber, after which the plate back-
ground was measured. A total of 6  104 cells were seeded in
the top chamber of eachwell, and theCIMplatewas left at room
temperature for 30minutes, allowing the cells to settle. The plate
was transferred to 37C/5% CO2 incubator, and measurements
were acquired with an interval of 15 minutes for 27 hours.
Human Tissue Materials
Human breast cancer and the adjacent non-tumor tissues
were from REPROCELL (Beltsville, MD). All breast
cancer tissue donors are TNM stage III breast cancer
patients. Samples were lysed using a Bullet Blender
24 Gold (Next Advance, Troy, NY; catalog number
BB24-AU), according to the cancer tissue homogenization
protocol. Briefly, the tissue samples were manually cut into
pieces. The samples were washed three times with 1/2 tube
volume of PBS to remove surface contaminants. The
samples were then placed in tubes with homogenization
beads (3.2-mm stainless steel beads; Next Advance; Cat
#SSB32; and 3.5-mm stainless steel UFO beads; Next
Advance; catalog number SSUFO35), add radio-
immunoprecipitation assay lysis buffer (25 mmol/L TRIS/
HCl, 150 mmol/L NaCl, 1% NP-40, 0.1% SDS, 0.5%
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Figure 1 Characterization of the lysosome associated protein transmembrane 4B (LAPTM4B) antibody. A: Schematic overview of the LAPTM4B gene,
transcript, and protein isoforms. The peptide used as an antigen is indicated between transmembrane domains 3 and 4. B: Wild-type (WT) A431 cells and
LAPTM4B knockout (KO) cells are stained with LAPTM4B antibody. C: WT A431 cells were incubated with fluorescent dextran for 2 hours to label endosomal
compartments (magenta), fixed, and stained with LAPTM4B antibody (green). Dotted box areas are shown in higher magnification in the bottom row. D: WT
and LAPTM4B KO A431 cells were treated with the indicated siRNAs, and LAPTM4B expression was assessed by Western blotting. E: Schematic overview of
CRISPR/Cas9-generated missense mutations of LAPTM4B-35 and LAPTM4B-24 start codons. Green indicates the start codon sequence of LAPTM4B isoforms, and
red the mutated sequence. F: Western blot showing LAPTM4B isoform expression in cell lines with mutated LAPTM4B-35 start codon (L4B-35M, clones 1 and 2)
or mutated LAPTM4B-24 start codon (L4B-24M, clones 1 and 2). Scale bars: 10 mm (B and C).
Expression and Regulation of LAPTM4B-24inhibitor Cocktail (Sigma-Aldrich; catalog number P8340)
in the ratio bead weight/sample weight/lysis buffer (1:1:2).
The samples were homogenized twice using blender set-
tings of speed 16 and time 4. The lysates were collected
and cleared by centrifugation 10 minutes at 11,800  g,
4C. The samples were analyzed by Western blotting.The American Journal of Pathology - ajp.amjpathol.orgHuman lung cancer tissue premade Western blot was from
BioCat (Heidelberg, Germany; catalog number 1511-PS),
human cancer tissues Western blots were from BioCat (cat-
alog number 1542-PS, catalog number 1545-PS), and human
healthy tissues Western blot membrane was from Novus
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 staining
Figure 2 The lysosome associated protein transmembrane 4B (LAPTM4B)-24 is up-regulated upon malignant transformation. A: Cancer cell lines and
healthy primary fibroblasts (Prim.fibr) were assessed for LAPTM4B expression by Western blotting. A total of 30 mg of protein from different cell lines were
loaded in each lane. Left panel: A representative experiment. Right panel: Quantification of n Z 3 experiments. B: LAPTM4B level in tumor tissue and paired
adjacent non-tumor tissue from four breast cancer patients was assessed by Western blotting. A total of 30 mg protein from different tissues was loaded per
lane. Left panel: A representative experiment. Right panel: Quantification of nZ 3 technical repeats. Red arrows indicate the location of 35-kDa proteins on
the Western blot. C: LAPTM4B level in tumor tissue and paired adjacent non-tumor tissue from three lung cancer patients, and in the lung cancer cell line A549,
were assessed by Western blotting. A total of 15 mg of protein from different tissues was loaded per lane. Right panel: Quantification of LAPTM4B levels with
LAPTM4B-24 expression in Patient 1 normal tissue set as 1. Data are expressed as means  SEM and are normalized to total protein content in the lane; and
LAPTM4B-35 level in A431 cells (A), Patient 1 tumor sample (B), or Patient 1 normal tissue (C) was set as 1. n Z 3 experiments (A) and technical repeats (B).
Zhou et alStatistical Analysis
All of the data are presented as means  SEM from at
least three independent experiments. Statistical signifi-
cance was calculated using the t-test for pairwise
comparisons. The level of statistical significance was set at
0.05.2022Results
Characterization of the Anti-LAPTM4B Antibody
To elucidate the expression of LAPTM4B isoforms in cells
and tissues, a monoclonal LAPTM4B antibody was made






















































































































































































































































Figure 3 Lysosome associated protein transmembrane 4B (LAPTM4B) protein isoforms in normal and cancer tissues. A: LAPTM4B levels in tumor tissues
from various origins are assessed by Western blotting. A total of 15 mg of protein from different tumor tissues was loaded per lane. B: Left panel: LAPTM4B
expression in healthy human tissues is assessed by Western blotting. A total of 50 mg of protein from different tissues was loaded per lane. Right panel:
Quantification of LAPTM4B expression with LAPTM4B-24 in heart set as 1.
Expression and Regulation of LAPTM4B-24Antibodies (Bromma, Sweden). The antigenic epitope is
located in the loop connecting transmembrane domains 3
and 4 of human LAPTM4B and is therefore present in both
isoforms (Figure 1A). In immunocytochemical stainings, the
antibody detected punctate structures in wild-type but not in
LAPTM4B KO A431 cells (Figure 1B). As expected,
LAPTM4B immunoreactivity displayed a high degree of
colocalization with dextran-labeled late endosomal com-
partments (Figure 1C). In Western blotting, the antibody
detected a major 24-kDa and a minor 35-kDa band in A431
wild-type cells. These bands were absent in LAPTM4B KO
cells and in cells treated with LAPTM4B siRNA
(Figure 1D).
The authors next investigated whether the 24-kDa and
35-kDa proteins stem from alternative translation start sites,
or if they represent different post-translational modifications
of the same protein. To this end, CRISPR/Cas9 and
homology-directed repair were used to generate cell lines
with targeted missense mutations that specifically interrupt
either the predicted start codon for LAPTM4B-35 or
LAPTM4B-24 (Figure 1E). In cells lacking the LAPTM4B-
35 ORF, the 35-kDa band was not expressed, but the
24-kDa protein was still detected, indicating that the two
isoforms are translated from different start codons. In furtherThe American Journal of Pathology - ajp.amjpathol.orgsupport of this, the 24-kDa band was absent from cells with
mutations in the predicted LAPTM4B-24 translation start
site (Figure 1F). Of note, all of the mutant cell lines dis-
played reduced levels of LAPTM4B mRNA (Supplemental
Figure S1). This agrees with the observation that transcripts
with interrupted start codons are often subject to enhanced
degradation.13 Together, these data indicate that the mono-
clonal antibody reliably detects LAPTM4B proteins by
immunofluorescence microscopy and Western blotting, and
verify the existence of two LAPTM4B isoforms translated
from alternative start codons. Interestingly, A431 cells
preferentially expressed LAPTM4B-24 rather than the ex-
pected 35-kDa isoform that is encoded by the longest ORF
or the transcript.
LAPTM4B-24 Is the Predominant Isoform in Human
Cell Lines and in Most Human Tissues
Because LAPTM4B-35 has been associated with poor
prognosis in cancers,8,14e18 the authors next assessed
whether this isoform was specifically up-regulated in human
cancer cell lines or primary tumor tissues. All of the tested
cancer cell lines displayed strong expression of LAPT
M4B-24 and low or undetectable levels of LAPTM4B-352023
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Figure 4 Lysosomal and proteasomal pathways are involved in the
rapid turnover of lysosome associated protein transmembrane 4B
(LAPTM4B)-24. A: Wild-type (WT) A431 cells were treated with 50 mg/mL
cycloheximide (CHX) for the indicated times, and endogenous LAPTM4B-24
expression is assessed by Western blotting. Left panel: A representative
experiment. Right panel: Quantification of n Z 3 experiments. The red
dashed line indicates the time point when half of the endogenous
LAPTM4B-24 has been degraded. B: WT A431 cells were treated with 1
mmol/L bafilomycin-A1 (Baf) and/or 20 mmol/L MG-132 (MG), together
with 50 mg/mL CHX for the indicated times, and endogenous LAPTM4B-24
expression is assessed by Western blotting. C: Quantification of data in (B).
Data are expressed as means  SEM and are normalized to 0 minutes time
point. nZ 3 experiments (A) and technical repeats (B); n  3 independent
experiments (C).
Zhou et al(Figure 2A). Intriguingly, in primary tumor tissue samples,
LAPTM4B-35 expression was negligible or absent, and most
tumors showed a predominant band at approximately 24 kDa
(Figure 2, B and C). LAPTM4B-24 was up-regulated in two
of four breast cancer samples (Figure 2B) and two of three
lung cancer samples compared with adjacent non-diseased
tissues (Figure 2C). The predominant expression of the
LAPTM4B-24 isoform was additionally observed in 17
tested tumor samples originating from 14 different tissue
types (Figure 3A). Moreover, LAPTM4B-24 was the only
isoform observed in healthy human primary fibroblasts and
the majority of normal tissues examined (Figures 2A and
3B). A notable exception is the brain, where only
LAPTM4B-35 was detected (Figure 3B). However, data-
mining revealed that LAPTM4B-35 appears not to be
essential in humans. The gnomAD database19 reports a frame
shift mutation (S75Afs) that specifically disrupts the ORF
of LAPTM4B-35 while leaving LAPTM4B-24 intact2024(Supplemental Figure S2A). The S75Afs allele is relatively
frequent (7.9%), and its homozygosity appears well tolerated
and is in fact enriched among the oldest individuals in the
database (Supplemental Figure S2B). The authors speculate
that the selective expression of LAPTM4B-35 in the human
brain might be related to maintaining sphingolipid homeo-
stasis or specific nutrient requirements of the central nervous
system. However, the lack of reported phenotypes in S75Afs
homozygous individuals suggests that LAPTM4B-24 may
compensate for LAPTM4B-35 function.
LAPTM4B-24 Is Physiologically Important in Mice
Of note, common laboratory animals including mouse, rat,
and zebrafish do not encode an ORF for LAPTM4B-35 in
their genomes, whereas LAPTM4B-24 is highly conserved
between the species (Supplemental Figure S3). Moreover,
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Figure 5 Lysosome associated protein trans-
membrane 4B (LAPTM4B)-24 protein levels are
regulated by nutrient signaling and ceramide. A:
Wild-type (WT) A431 cells were treated with Earle
Balanced Salt Solution (EBSS), with or without
protein degradation inhibitors [1 mmol/L
bafilomycin-A1 (Baf) and 20 mmol/L MG-
132(MG)], for the indicated times. Endogenous
LAPTM4B-24 expression is assessed by Western
blotting. Left panel: A representative experiment.
Right panel: Quantification of nZ 4 experiments.
B: WT A431 cells were starved 1 hour in EBSS and
refed with stimulation medium for 20 minutes or
40 minutes. Endogenous LAPTM4B-24 expression
is assessed by Western blotting. Left panel:
Timeline of starving and refeeding cells, and a
representative experiment. Right panel: Quanti-
fication of n Z 3 experiments. C: WT A431 cells
were treated with indicated concentrations of C6-
ceramide (Cer) for 6 hours, and endogenous
LAPTM4B-24 expression is assessed by Western
blotting. Left panel: A representative experiment.
Right panel: Quantification of nZ 3 experiments.
D: The main lysosomal ceramide generating and
degrading enzymes. E: WT A431 cells were treated
with siRNAs against SMPD1 or GBA, and endoge-
nous LAPTM4B-24 expression is assessed by
Western blotting. Top panel: A representative
experiment. Bottom panel: Quantification of
n Z 3 experiments. F: Endogenous LAPTM4B-24
expression in WT and ASAH1 knockout (KO) cells
was assessed by Western blotting. Top panel: A
representative experiment. Bottom panel: Quan-
tification of n Z 4 experiments. Data are
expressed as means  SEM and are normalized to
0 hour time point (A and B), 0 mmol/L ceramide
condition (C), Ctrl (E), or WT (F). n Z 4 experi-
ments (A and F); nZ 3 experiments (B, C, and E).
*P < 0.05; yP < 0.05 versus 0 mmol/L; zP < 0.05
versus control; xP < 0.05 versus WT. ASAH1, acid
ceramidase; Cer, ceramide; EAA, stimulation me-
dium; GBA, glucocerebrosidase; GlcCer, gluco-
sylceramide; SM, sphingomyelin; SMPD1, acid
sphingomyelinase; Sph, sphingosine.
Expression and Regulation of LAPTM4B-24and die at the preweaning stage (International Mouse Phe-
notyping Consortium20), suggesting an essential function
for LAPTM4B-24.
LAPTM4B-24 and LAPTM4B-35 Display Different
Subcellular Distributions and Functions
Studies of LAPTM4B have frequently relied on over-
expressing the protein.16,21e24 To dissect the functional
properties of the individual isoforms, cells expressing either
LAPTM4B-24 or -35 on a LAPTM4B knockout backgroundThe American Journal of Pathology - ajp.amjpathol.orgwere compared. The two isoforms displayed clear differ-
ences in their subcellular distribution. LAPTM4B-24 was
predominantly endosomal, whereas LAPTM4B-35 was
found both in endosomes and to a substantial degree in the
plasma membrane (Supplemental Figure S4, AeD).
Because LAPTM4B has been shown to regulate cell
migration22,23 and mTORC1 signaling,6,25 the authors next
assessed isoform-specific effects on these pathways. Label-
free real-time monitoring of cells using xCELLigence12
revealed that cell migration was stimulated by LAPTM4B-
35, but not by LAPTM4B-24 (Supplemental Figure S4E).2025
Zhou et alMoreover, LAPTM4B-35 increased AKT phosphorylation
at Ser 473, and this effect was not seen in LAPTM4B-
24eexpressing cells (Supplemental Figure S4F). These
results agree with previous studies showing that the PPRP
motif in the N-terminus of LAPTM4B-35 regulates AKT
and promotes cancer cell migration.4,22 However, the
contribution of this pathway in tumor progression in vivo
remains open, considering that LAPTM4B-35 was present
only at low levels and in a small subset of tumors (Figures 2,
B and C, and 3A). To investigate LAPTM4B isoform effects
on mTORC1 signaling, cells were starved for 1 hour with
EBSS, and the phosphorylation of the mTORC1 substrates
ribosomal protein S6 kinase B1 (S6K), eukaryotic trans-
lation initiation factor 4E binding protein (4EBP), and unc-
51 like autophagy activating kinase 1 (ULK1) were assessed
upon refeeding with stimulation medium (complete me-
dium/EBSS, 1:1). These experiments showed that S6K,
4EBP, and ULK1 phosphorylation was similarly stimulated
by LAPTM4B-24 and -35 (Supplemental Figure S5). These
data reinforce the notion that LAPTM4B functions in
nutrition signaling. Accordingly, the main interaction part-
ners of LAPTM4B are endosomal solute carriers and amino
acid transporters,6,25 necessary for cellular metabolism.
LAPTM4B-24 Is Degraded by Lysosomal and
Proteasomal Pathways
The new antibody was used in studying LAPTM4B-24
protein turnover. In A431 cells treated with the protein
synthesis inhibitor cycloheximide, endogenous LAPTM4B-
24 was rapidly lost with a half-time of approximately 1 hour
(Figure 4A). A similar result was obtained in cells stably
overexpressing LAPTM4B-24 (Supplemental Figure S6A),
suggesting that a post-translational mechanism is respon-
sible for the rapid loss of LAPTM4B.
To dissect the pathways involved in endogenous
LAPTM4B-24 degradation, cells were treated with the
V-ATPase inhibitor bafilomycin-A1 to block lysosomal
function, or with MG-132 to inhibit proteasomes. Both
bafilomycin-A1 and MG-132 strongly attenuated LAPTM4B-
24 degradation in cycloheximide-treated cells (Figure 4, B and
C). This indicates that both lysosomal and proteasomal path-
ways contribute to the turnover of endogenous LAPTM4B-24.
Indeed, earlier data provided evidence that overexpressed
LAPTM4B can be ubiquitinated by NEDD4,7 sorted into late
endosomal compartments,9,26 and lysosomally degraded.27
LAPTM4B-24 Is Regulated by Nutrient Availability and
Ceramide
Considering the rapid turnover of LAPTM4B and its role in
mTORC1 signaling,6,25 it was next assessed whether
endogenous LAPTM4B is regulated by nutrient availability.
Indeed, starvation with EBSS induced a decrease in cellular
LAPTM4B-24, which was blocked by inhibitors of lyso-
somal and proteasomal protein degradation (Figure 5A). The2026LAPTM4B level was rapidly restored by refeeding stimula-
tion medium to the starved cells (Figure 5B), indicating that
LAPTM4B expression is responsive to nutrient availability. It
has been previously shown that LAPTM4B interacts with
ceramide,6,9 a simple sphingolipid regulating autophagy28,29
and mTORC1 signaling.6,30,31 The authors therefore hy-
pothesized that ceramide may in part exert its effect by
regulating LAPTM4B-24 expression. In support of this,
C6-ceramide was found to increase endogenous LAPTM4B-
24 protein in a concentration-dependent manner (Figure 5C
and Supplemental Figure S6, B and C). Instead, LAPTM4B-
24 protein level was not increased by the other lipids tested
(cholesterol, oleic acid or C6-sphingomyelin) and was not
markedly affected by glucose deprivation (Supplemental
Figure S7), suggesting that ceramide exerts a specific effect
in LAPTM4B regulation.
To investigate whether endogenously generated ceramide
affects LAPTM4B-24 expression, A431 cells were depleted
of lysosomal sphingolipid catabolizing enzymes (Figure 5D).
Reducing lysosomal ceramide generation by knockdown of
either acid sphingomyelinase (SMPD1) or glucocerebrosidase
(GBA) caused a decrease in cellular LAPTM4B (Figure 5E).
Conversely, inhibition of lysosomal ceramide degradation by
knockout of acid ceramidase (ASAH1 KO) lead to moderately
increased levels of LAPTM4B (Figure 5F). Together, this
suggests that ceramide may exert a dual effect on
LAPTM4B, by promoting its stabilization (this work) as well
as by facilitating its interaction with lysosomal amino acid
transporters to regulate mTORC1 signaling.6Discussion
This study establishes the 24-kDa form of LAPTM4B that
lacks the extreme N-terminus of the protein as the predomi-
nantly expressed isoform in the majority of normal and ma-
lignant human cells and tissues studied. This study’s results
argue that the 35- and 24-kDa LAPTM4B isoforms are
functionally distinct and demonstrate that in human cells,
LAPTM4B-24 is subject to rapid turnover via both lysosomal
and proteasomal degradation. LAPTM4B-24 is physiologi-
cally regulated by nutrient availability, with its levels being
stabilized by lysosomal protein and lipid degradation prod-
ucts, that is, essential amino acids and ceramide.
Earlier studies have reported a strong association between
LAPTM4B transcript levels and poor outcome in several
cancers.3,32 Up-regulation of the LAPTM4B transcript has
been observed in most carcinomas of the lung (88%), colon
(67%), uterus (83%), breast (51%), and ovary (69%).32 The
detailed role of LAPTM4B in cancers remains unknown, and
there are reports suggesting that both high3,33 and low9,34
expression may promote chemotherapy resistance. An
increasing number of studies point to a role for LAPTM4B in
mTORC1 and autophagy signaling, and both mTORC1
activating6,25 or autophagy promoting33,35 effects have been
proposed. This suggests that LAPTM4B itself may not be aajp.amjpathol.org - The American Journal of Pathology
Expression and Regulation of LAPTM4B-24central regulator of autophagy and chemotherapy resistance,
but rather exerts context dependent modulation of these
processes. Interpretation of the available data is further
complicated by the fact that studies frequently utilize over-
expression of either the 24- or 35-kDa LAPTM4B isoform
that exhibits in part distinct effects on cellular functions.
Although increased expression of LAPTM4B-35 has been
proposed as a driving factor of cancer progression, our
findings suggest that the expression of this isoform is low or
negligible in most tumors. Thus, it seems plausible that up-
regulation of the 24-kDa isoform may be responsible for
many of the observed detrimental effects of LAPTM4B in
cancers. Interestingly, recent studies have identified a minor
polymorphic variant termed LAPTM4B*2 that contains a
19-bp tandem repeat in the 50UTR.36,37 This allele has been
shown to predict poor prognosis in malignant melanoma,
colorectal and esophageal and prostate cancers.38e40 Whether
this variant allele promotes the expression of LAPTM4B-35
will be interesting to address in future studies.
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